Based on lapatinib innovative near-infrared fluorescent probes targeting HER1/HER2 for in vivo tumors imaging

Li, Changsheng; Lin, Qiao; Hu, Fangrong; Bao, Ruichu; Cai, Huiming; Gu, Yueqing

doi:10.1016/j.bios.2022.114503

Cited by 3 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Biomedical optical imaging has emerged as a powerful tool to be used in pre-clinical research, clinical diagnosis, and intraoperative detection of tumors. − Several HER2-targeted fluorescent probes that emit light in the visible (400–700 nm) and near-infrared window one region [near-infrared window one region I (NIR-I), 700–1000 nm] have been developed for imaging HER2-positive tumors and show promise for cancer detection . Recently, near-infrared window II region (NIR-II, 1000–1700 nm) imaging has demonstrated many advantages such as minimal autofluorescence, low light scattering, increased imaging sensitivity, and tissue penetration depth over the traditional visible and NIR-I imaging techniques, and it provides a promising, non-invasive, and real-time imaging technique for monitoring diseases in vivo .…”

Section: Introductionmentioning

confidence: 99%

Development of a Novel HER2-Targeted Peptide Probe for Dual-Modal Imaging of Tumors

Cao

Lai

et al. 2023

J. Med. Chem.

View full text Add to dashboard Cite

Human epidermal growth factor receptor 2 (HER2) may serve as a valid target for diagnosis of cancer. The probes with capability for near-infrared window one region II (NIR-II) and positron emission tomography (PET) dual-modal imaging are highly desired for HER2-positive tumor detection. Herein, three HER2-targeted peptides were designed and further modified with indocyanine green (ICG) and 2,2′,2″,2″-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetic acid (DOTA), which were used for NIR-II imaging and complexation with 68Ga for PET. Among the resulted probes (DOTA-ZC01-ICG, DOTA-KSP-ICG, and DOTA-ZC02-ICG), NIR-II imaging revealed that DOTA-ZC02-ICG had the best tumor imaging performance in SKOV3 tumor-bearing mice. The highest T/N ratio (5.4) was achieved at 4 h post-injection. Furthermore, DOTA-ZC02-ICG was radiolabeled with 68Ga to generate [68Ga]-DOTA-ZC02-ICG for PET, and it clearly delineated at 0.5, 1, and 2 h post-injection. The tumor uptake reached 1.9 %ID/g at 0.5 h, and the tumor uptakes were significantly inhibited in the blocking study (p < 0.05). Overall, it provides a promising technique for tumor dual-modal imaging and a new molecular scaffold for developing HER2-targeted theranostic agents.

show abstract

Section: Introductionmentioning

confidence: 99%

Development of a Novel HER2-Targeted Peptide Probe for Dual-Modal Imaging of Tumors

Cao

Lai

et al. 2023

J. Med. Chem.

View full text Add to dashboard Cite

show abstract

Design of a selective and water-soluble fluorescent probe targeting Tau fibrils for intracellular and in vivo imaging

Zhou²,

Liu

et al. 2023

Sensors and Actuators B: Chemical

View full text Add to dashboard Cite

PDGFRβ targeted innovative imaging probe for pancreatic adenocarcinoma detection

Gao

et al. 2023

Talanta

View full text Add to dashboard Cite

Based on lapatinib innovative near-infrared fluorescent probes targeting HER1/HER2 for in vivo tumors imaging

Cited by 3 publications

References 31 publications

Development of a Novel HER2-Targeted Peptide Probe for Dual-Modal Imaging of Tumors

Development of a Novel HER2-Targeted Peptide Probe for Dual-Modal Imaging of Tumors

Design of a selective and water-soluble fluorescent probe targeting Tau fibrils for intracellular and in vivo imaging

PDGFRβ targeted innovative imaging probe for pancreatic adenocarcinoma detection

Contact Info

Product

Resources

About